Journal
CLINICAL CANCER RESEARCH
Volume 12, Issue 18, Pages 5277-5287Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-06-0436
Keywords
-
Categories
Funding
- NCI NIH HHS [CA105490, CA084291, CA101973, CA111292] Funding Source: Medline
Ask authors/readers for more resources
The use of genetically engineered cancer-prone mice as relevant surrogates for patients during the development of pertinent clinical applications is an unproven expectation that awaits direct demonstration. Despite the generally disappointing findings using tumor xenografts and certain early transgenic cancer models to predict therapeutic efficacy in patients, the dramatic progress of mouse models in recent years engenders optimism that the newest generation of mouse models will provide a higher standard of predictive utility in the process of drug development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available